Basking Biosciences Revenue and Competitors
Employee Data
- Basking Biosciences has 10 Employees.
- Basking Biosciences grew their employee count by 11% last year.
Basking Biosciences's People
| Name | Title | Email/Phone |
|---|
Basking Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $1.7M | 11 | 0% | N/A | N/A |
#3 | $0.8M | 5 | 0% | N/A | N/A |
#4 | $5.1M | 33 | 14% | N/A | N/A |
#5 | $64.6M | 417 | 2% | N/A | N/A |
#6 | $1.7M | 11 | -8% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $7.4M | 48 | -41% | N/A | N/A |
#9 | $0.6M | 4 | 0% | N/A | N/A |
#10 | $0.9M | 10 | -9% | N/A | N/A |
What Is Basking Biosciences?
Basking Biosciences is developing a novel first-line therapy (BB-031) targeting von Willebrand Factor (vWF), along with a direct acting reversal agent (BB-025) to immediately neutralize the pharmacological effect of BB-031 in the event of bleeding. BB-031 is an RNA aptamer optimized for rapid onset of action and short duration of effect. BB-031 is being evaluated in patients with acute ischemic stroke (AIS) in the RAISE trial, a two-part Phase 2 study assessing the safety and preliminary efficacy of the investigational drug candidate. The technology is based on two decades of translational research on RNA aptamers as therapeutic agents for cardiovascular diseases.\n \n\n \n \n Show more\n \n\n \n\n\n \n \n Show less
keywords:N/A
N/A
Total Funding
10
Number of Employees
N/A
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Columbus
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 10 | N/A | N/A |
#2 | $0.9M | 10 | -17% | N/A |
#3 | $1.6M | 10 | -9% | N/A |
#4 | $1.5M | 10 | -9% | N/A |
#5 | $2M | 10 | 0% | N/A |